 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: The relationship between the neutrophil/lymphocyte ratio (NLR) and the efficacy of avelumab combined with axitinib or sunitinib in the treatment of advanced renal cell carcinoma (RCC): from the JAVELIN Renal 101 study

Clin Cancer Res: The relationship between the neutrophil/lymphocyte ratio (NLR) and the efficacy of avelumab combined with axitinib or sunitinib in the treatment of advanced renal cell carcinoma (RCC): from the JAVELIN Renal 101 study

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

stem cell meat

single cell suspension

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the JAVELIN Renal 101 clinical study, the efficacy and safety of PD-L1 inhibitor avelumab combined with axitinib (axitinib) versus sunitinib ( sunitinib ) in the treatment of previously untreated patients with advanced renal cell carcinoma (RCC) were studied
.

In the first data analysis, compared with sunitinib, avelumab + axitinib significantly improved the patient’s PFS (HR, 0.

Through the analysis of the JAVELIN Renal 101 clinical study (NCT02684006), the relationship between baseline NLR and progression-free survival (PFS) and overall survival (OS) in the avelumab combined with axitinib or sunitinib group was analyzed Retrospective analysis
.

Multivariate Cox regression analysis of PFS and OS related factors

Among the 434 patients in the avelumab+axitinib group and the 439 patients in the sunitinib group, NLR was evaluable

In both treatment groups, it was observed that the PFS of patients with low-median NLR was significantly longer than that of patients with median-high NLR

PFS

PFSPFS

In both treatment groups, it was observed that the OS of patients with low-median NLR was significantly longer than that of patients with median-high NLR
.

The HR of the Avelumab+axitinib group was 0.

In both treatment groups, it was observed that the OS of patients with low-median NLR was significantly longer than that of patients with median-high NLR

OSOS

In both treatment groups, it was observed that the ORR of patients with low-median NLR was significantly higher than that of patients with median-high NLR
.

The ORRs of patients with low-median NLR and median-high NLR in the Avelumab+axitinib group were 57.

In both treatment groups, it was observed that the ORR of patients with low-median NLR was significantly higher than that of patients with median-high NLR

ORR

ORR ORR

In the Avelumab+axitinib group with median-high NLR, there was no difference in PFS or OS between low-median TMB patients and median-high TMB patients
.

Among patients with low-median NLR in the Avelumab+axitinib group, there were differences in PFS and OS between low-median TMB patients and median-high TMB patients (PFS: HR=0.

In the Avelumab+axitinib group with median-high NLR, there was no difference in PFS or OS between low-median TMB patients and median-high TMB patients
.
Among patients with low-median NLR in the Avelumab+axitinib group, there were differences in PFS and OS between low-median TMB patients and median-high TMB patients (PFS: HR=0.
63 95% CI, 0.
369-1.
063; P=0.
0406; OS: HR=0.
35 95% CI, 0.
112-1.
122; P=0.
0333)
.
No difference was observed in the sunitinib group
.
At the same time, NLR/TMB classification was not related to ORR in the two treatment groups
.

In summary, studies have shown that NLR can be used as a prognostic marker for patients with advanced renal cell carcinoma (RCC) who receive avelumab combined with axitinib or sunitinib
.

In summary, studies have shown that NLR can be used as a prognostic marker for patients with advanced renal cell carcinoma (RCC) who receive avelumab combined with axitinib or sunitinib
.
Studies have shown that NLR can be used as a prognostic marker for patients with advanced renal cell carcinoma (RCC) who receive avelumab combined with axitinib or sunitinib
.
Studies have shown that NLR can be used as a prognostic marker for patients with advanced renal cell carcinoma (RCC) who receive avelumab combined with axitinib or sunitinib
.

Original source:

Bilen MA, Rini BI, Voss MH, et al.
Association of Neutrophil-to-Lymphocyte Ratio With Efficacy of First-Line Avelumab Plus Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
Clin Cancer Res.
2021 Nov 17:clincanres.
1688.
2021.
doi: 10.
1158/1078-0432.
CCR-21-1688.
Epub ahead of print.
PMID: 34789480.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.